James C Mulloy PhD


James C Mulloy PhD
Asst ProfessorCollege of Medicine--UCjames.Mulloy@cchmc.org
S7.603/ML 7013 3333 Burnet Ave Cincinnati OH 45229
Phone:513-636-1844Fax: 513-636-3768
  • Molecular Biology and Cancer Genetics

General Research Interest

Leukemia, hematopoiesis, transcription factor activity, epigenetics, xenograft leukemia model, survival signaling in leukemia

Research Description

Research in the Mulloy Laboratory focuses on using human hematopoietic stem/progenitor cells (HSPC) to model leukemia. The prevailing theory is that acute myeloid leukemia is a stem cell disease. We believe the technology and expertise are now available that permit us to use primary human HSPC to dissect the stepwise progression of human AML. As a proof of principal, we have expressed the AML1-ETO fusion protein in human CD34+ cells by retroviral transduction and characterized the genetic and functional alterations that occur due to expression of this oncogene These studies have recently been extended to two additional oncogenes, CBFb-MYH11 and MLL-AF9.

Transinstitutional Work

The Mulloy lab is currently collaborating with the laboratory of Dr. Guido Marcucci, using constitutively active mutants of the c-kit protein in cooperative leukemia initiation studies with the AML1-ETO and CBFb-MYH11 oncoproteins.

Current Publications

  • Huang GDownregulation of RUNX1/CBFß by MLL fusion proteins enhances hematopoietic stem cell self-renewal.Blood 123 1729-38 3/13/2014
  • Grimes HLTherapeutic antagonists of microRNAs deplete leukemia-initiating cell activity.J Clin Invest 124 222-36 1/2/2014
  • Starczynowski DTAn MDS xenograft model utilizing a patient-derived cell line.Leukemia 12/11/2013
  • Mulloy JCA new inducible model for t(8;21) AML.EMBO Mol Med 5 1795-7 12/1/2013
  • Goyama S, Schibler J, Cunningham L, Zhang Y, Rao Y, Nishimoto N, Nakagawa M, Olsson A, Wunderlich M, Link KA, Mizukawa B, Grimes HL, Kurokawa M, Liu PP, Huang G, Mulloy JCTranscription factor RUNX1 promotes survival of acute myeloid leukemia cells.J Clin Invest 123 4979 11/1/2013
  • Goyama S, Mulloy JCNF-?B: a coordinator for epigenetic regulation by MLL.Cancer Cell 24 401-2 10/14/2013
  • Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, Sun C, Saddoughi SA, Bielawski J, Blum W, Klisovic RB, Solt JA, Byrd JC, Volinia S, Cortes J, Huettner CS, Koschmieder S, Holyoake TL, Devine S, Caligiuri MA, Croce CM, Garzon R, Ogretmen B, Arlinghaus RB, Chen CS, Bittman R, Hokland P, Roy DC, Milojkovic D, Apperley J, Goldman JM, Reid A, Mulloy JC, Bhatia R, Marcucci G, Perrotti DPP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.J Clin Invest 123(10) 4144-57 10/1/2013
  • Goyama S, Schibler J, Cunningham L, Zhang Y, Rao Y, Nishimoto N, Nakagawa M, Olsson A, Wunderlich M, Link KA, Mizukawa B, Grimes HL, Kurokawa M, Liu PP, Huang G, Mulloy JCTranscription factor RUNX1 promotes survival of acute myeloid leukemia cells.J Clin Invest 123(9) 3876-88 9/3/2013
  • Huang H, Jiang X, Li Z, Li Y, Song CX, He C, Sun M, Chen P, Gurbuxani S, Wang J, Hong GM, Elkahloun AG, Arnovitz S, Wang J, Szulwach K, Lin L, Street C, Wunderlich M, Dawlaty M, Neilly MB, Jaenisch R, Yang FC, Mulloy JC, Jin P, Liu PP, Rowley JD, Xu M, He C, Chen JTET1 plays an essential oncogenic role in MLL-rearranged leukemia.Proc Natl Acad Sci U S A 110(29) 11994-9 7/16/2013
  • Chen P, Price C, Li Z, Li Y, Cao D, Wiley A, He C, Gurbuxani S, Kunjamma RB, Huang H, Jiang X, Arnovitz S, Xu M, Hong GM, Elkahloun AG, Neilly MB, Wunderlich M, Larson RA, Le Beau MM, Mulloy JC, Liu PP, Rowley JD, Chen JmiR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemia.Proc Natl Acad Sci U S A 110(28) 11511-6 7/9/2013
  • Rhyasen GW, Bolanos L, Fang J, Jerez A, Wunderlich M, Rigolino C, Mathews L, Ferrer M, Southall N, Guha R, Keller J, Thomas C, Beverly LJ, Cortelezzi A, Oliva EN, Cuzzola M, Maciejewski JP, Mulloy JC, Starczynowski DTTargeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.Cancer Cell 24(1) 90-104 7/8/2013
  • Bell-Horwath TR, Vadukoot AK, Thowfeik FS, Li G, Wunderlich M, Mulloy JC, Merino EJNovel ROS-activated agents utilize a tethered amine to selectively target acute myeloid leukemia.Bioorg Med Chem Lett 23(10) 2951-4 5/15/2013
  • Wunderlich M, Mizukawa B, Chou FS, Sexton C, Shrestha M, Saunthararajah Y, Mulloy JCAML cells are differentially sensitive to chemotherapy treatment in a human xenograft model.Blood 121(12) e90-7 3/21/2013
  • Goyama S, Mulloy JCMaking healthy stem cells: the new role of TPO.Cell Stem Cell 12(1) 8-9 1/3/2013
  • Jiang X, Huang H, Li Z, He C, Li Y, Chen P, Gurbuxani S, Arnovitz S, Hong GM, Price C, Ren H, Kunjamma RB, Neilly MB, Salat J, Wunderlich M, Slany RK, Zhang Y, Larson RA, Le Beau MM, Mulloy JC, Rowley JD, Chen JMiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia.Proc Natl Acad Sci U S A 109(47) 19397-402 11/20/2012
  • Zhang Y, Yan X, Sashida G, Zhao X, Rao Y, Goyama S, Whitman SP, Zorko N, Bernot K, Conway RM, Witte D, Wang QF, Tenen DG, Xiao Z, Marcucci G, Mulloy JC, Grimes HL, Caligiuri MA, Huang GStress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentiation in Mll partial tandem duplication (Mll-PTD) hematopoietic stem/progenitor cells.Blood 120(5) 1118-29 8/2/2012
  • Chou FS, Griesinger A, Wunderlich M, Lin S, Link KA, Shrestha M, Goyama S, Mizukawa B, Shen S, Marcucci G, Mulloy JCThe thrombopoietin/MPL/Bcl-xL pathway is essential for survival and self-renewal in human preleukemia induced by AML1-ETO.Blood 120(4) 709-19 7/26/2012
  • Fang J, Rhyasen G, Bolanos L, Rasch C, Varney M, Wunderlich M, Goyama S, Jansen G, Cloos J, Rigolino C, Cortelezzi A, Mulloy JC, Oliva EN, Cuzzola M, Starczynowski DTCytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1.Blood 120(4) 858-67 7/26/2012
  • Alvarez SChromatin modifications induced by the AML1-ETO fusion protein reversibly silence its genomic targets through AML1 and Sp1 binding motifs.Leukemia 26(6) 6/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu